Pyrazolam

Pyrazolam
Clinical data
Routes of; administration	Oral, Sublingual, rectal
Legal status
Legal status	AU: S4; CA: Schedule IV; DE: NpSG (Industrial and scientific use only); UK: Class C; US: Unscheduled;
Pharmacokinetic data
Elimination half-life	17 hours
Identifiers
	IUPAC name 8-Bromo-1-methyl-6-(pyridin-2-yl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine;
CAS Number	39243-02-2;
PubChem CID	12562545;
ChemSpider	15417688;
UNII	8LH16383PK;
ChEMBL	ChEMBL3246831;
CompTox Dashboard (EPA)	DTXSID101043303 ;
Chemical and physical data
Formula	C16H12BrN5
Molar mass	354.211 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NN=C2CN=C(C3=NC=CC=C3)C3=CC(Br)=CC=C3N12;
	InChI InChI=1S/C16H12BrN5/c1-10-20-21-15-9-19-16(13-4-2-3-7-18-13)12-8-11(17)5-6-14(12)22(10)15/h2-8H,9H2,1H3; Key:BGRWSFIQQPVEML-UHFFFAOYSA-N;

Pyrazolam (SH-I-04) is a benzodiazepine derivative originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s. It has since been "rediscovered" and sold as a designer drug since 2012.

Pyrazolam has structural similarities to alprazolam and bromazolam. Unlike other benzodiazepines, pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine.

Clinical data

Routes of administration	Oral, Sublingual, rectal
Legal status
Legal status	AU: S4 CA: Schedule IV DE: NpSG (Industrial and scientific use only) UK: Class C US: Unscheduled
Pharmacokinetic data
Elimination half-life	17 hours
Identifiers
IUPAC name 8-Bromo-1-methyl-6-(pyridin-2-yl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
CAS Number	39243-02-2
PubChem CID	12562545
ChemSpider	15417688
UNII	8LH16383PK
ChEMBL	ChEMBL3246831
CompTox Dashboard (EPA)	DTXSID101043303
Chemical and physical data
Formula	C₁₆H₁₂BrN₅
Molar mass	354.211 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=NN=C2CN=C(C3=NC=CC=C3)C3=CC(Br)=CC=C3N12
InChI InChI=1S/C16H12BrN5/c1-10-20-21-15-9-19-16(13-4-2-3-7-18-13)12-8-11(17)5-6-14(12)22(10)15/h2-8H,9H2,1H3 Key:BGRWSFIQQPVEML-UHFFFAOYSA-N